Pfizer Says COVID Vaccine for 5- to 11-Year-Olds Is Safe and Shows ‘Robust’ Antibody Response, Experts Say Not So Fast

“Pfizer plans to request Emergency Use Authorization from the FDA based on data from its phase 2/3 trial for children ages 5 to 11, as experts question the company’s data and need for kids to be vaccinated against COVID.”

Pfizer Says COVID Vaccine for 5- to 11-Year-Olds Is Safe and Shows ‘Robust’ Antibody Response, Experts Say Not So Fast • Children’s Health Defense (childrenshealthdefense.org)

Published by markskidmore

Mark Skidmore is Professor of Economics at Michigan State University where he holds the Morris Chair in State and Local Government Finance and Policy. His research focuses on topics in public finance, regional economics, and the economics of natural disasters. Mark created the Lighthouse Economics website and blog to share economic research and information relevant for navigating tumultuous times.

Leave a Reply

%d bloggers like this: